Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Partner Santhera Commences Phase III Trial For Duchenne Muscular Dystrophy Drug

This article was originally published in PharmAsia News

Executive Summary

Japan's Takeda disclosed recently that Swiss partner Santhera has commenced a pivotal Phase III trial for Catena/Sovrima (idebenone), which could be the first drug to treat Duchenne Muscular Dystrophy, a rare disease that affects an estimated 30,000 European and North American male patients mainly in their teens

You may also be interested in...



Duchenne Muscular Dystrophy: Pipeline And Partnering Snapshot

A full pipeline of symptomatic and disease-modifying treatments for Duchenne will transform a long dormant orphan market into a hotly contested commercial prize. But some issues, foremost the scarcity of trial patients, threaten to stall progress in the field.

Takeda Takes Back Actos Rights from Eli Lilly, Sets Course For Own Geographic Expansion

Takeda is taking back marketing rights to type 2 diabetes treatment Actos (pioglitazone) from Eli Lilly in Canada and six other countries as early as this year, according to the two companies

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

SC072954

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel